Oncology

News

With FDA okay, AZ takes on MSD in early-stage lung cancer

AstraZeneca has claimed FDA approval for its immunotherapy Imfinzi before and after surgery for non-small cell lung cancer, setting up a contest with MSD's rival Keytruda.

News

AZ gets landmark approval for Imfinzi/Lynparza combo

AstraZeneca has become the first company to get approval for the combination of an immunotherapy with a PARP inhibitor for treating endometrial cancer.

News

Second time lucky at FDA for Citius' lymphoma drug

At the second attempt, the FDA has approved Citius Pharmaceuticals' marketing application for Lymphir, a new version of a lymphoma therapy withdrawn from sale several years ago.

News

Person with their hand covering their face

More bad news for TIGIT as MSD stops another trial

Another TIGIT trial failure has been abandoned, casting a shadow once again over the target as a cancer immunotherapy strategy.

News

Mallinckrodt sells Therakos unit on at a discount

Ireland-headquartered pharma group Mallinckrodt has agreed to divest its subsidiary Therakos to private equity firm CVC Capital Partners for $925 million, well below the $1.33 billion it pa

News

Novartis, Viatris latest targets of Henrietta Lacks lawsuits

Novartis and Viatris have become the latest pharma companies to be named in lawsuits claiming that they profited from the unlawful use of HeLa cells derived from cells taken from a cancer p

With FDA okay, AZ takes on MSD in early-stage lung cancer

AZ gets landmark approval for Imfinzi/Lynparza combo

Second time lucky at FDA for Citius' lymphoma drug

More bad news for TIGIT as MSD stops another trial

Mallinckrodt sells Therakos unit on at a discount

Novartis, Viatris latest targets of Henrietta Lacks lawsuits

An AI supercomputer and discovering next-gen brain disorder ...

How to meet your physicians where they are online

Oncology

Editor's Picks